DUK
50
-2
ACN
70
5
MPC
47
3
AES
41
2
EQT
57
-3
NKE
33
2
SIG
47
-2
KO
44
2
ETR
68
-3
SRE
66
-3
UPS
50
9
LOW
58
2
PWR
71
-3
SHW
70
2
CVX
38
6
HSY
43
3
NWS
79
-4
TAP
64
4
JBHT
63
-5
COF
63
-4
DUK
50
-2
ACN
70
5
MPC
47
3
AES
41
2
EQT
57
-3
NKE
33
2
SIG
47
-2
KO
44
2
ETR
68
-3
SRE
66
-3
UPS
50
9
LOW
58
2
PWR
71
-3
SHW
70
2
CVX
38
6
HSY
43
3
NWS
79
-4
TAP
64
4
JBHT
63
-5
COF
63
-4
Financhill
Back

Alaunos Therapeutics 10K Form

Sell
20

TCRT
Alaunos Therapeutics

Last Price:
2.32
Seasonality Move:
11.94%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive TCRT News And Ratings

See the #1 stock for the next 7 days that we like better than TCRT

TCRT Financial Statistics

Sales & Book Value

Annual Sales: $5K
Cash Flow: $-1.68M
Price / Cash Flow: 0
Annual Sales: $2.36
Price / Book: 1.04

Profitability

EPS (TTM): -12.70800
Net Income (TTM): $-19.13M
Gross Margin: $0
Return on Equity: -189.69%
Return on Assets: -144.17%

Alaunos Therapeutics Earnings Forecast

Key Alaunos Therapeutics Financial Ratios

  • The Selling, General & Administrative Expenses for TCRT have been equal to 244,380.00% of Gross Profit Margin.
  • The Research & Development expenses have been 325,580.00% of Revenue.
  • The Interest Expense is -5.47% of Operating Income.
  • The Net Earning history of TCRT is -702,800.00% of Total Revenues.
  • Per Share Earnings over the last 23 years have been positive in 13 years.

Alaunos Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: TCRT
Website: alaunos.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 5.16
Quick Ratio: 2.72

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

TCRT Technical Analysis vs Fundamental Analysis

Sell
20
Alaunos Therapeutics (TCRT) is a Sell

Is Alaunos Therapeutics a Buy or a Sell?